SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Core Insights - Bluejay Diagnostics, Inc. announced results from the SYMON-I study, which investigates the role of interleukin-6 (IL-6) in patients with sepsis and septic shock [1][2] Study Findings - The primary analysis of the SYMON-I study indicates that IL-6 levels measured within 24 hours of sepsis or septic shock diagnosis can predict patient mortality up to 28 days [2] - Secondary outcomes revealed that IL-6 levels are also predictive of in-hospital mortality, while traditional clinical tests like lactate and SOFA scores did not predict 28-day mortality [3] Future Directions - Bluejay Diagnostics plans to initiate the SYMON-II pivotal study in Q3 2024 to validate SYMON-I findings, with the intention to support a 510(k) application to the FDA in 2025 [4][8] - The Symphony IL-6 Test aims to assist in assessing the cumulative 28-day risk of all-cause mortality for sepsis patients in the ICU [4] Company Overview - Bluejay Diagnostics is focused on developing rapid and accessible biomarker testing, with the Symphony IL-6 Test being its lead product candidate designed for sepsis triage [9]